IP22-25: PDE5 Inhibitors and Cardiovascular Outcomes in Men with ED: Propensity-Weighted Hazard Ratios over 12 Months

IP22-25: PDE5 Inhibitors and Cardiovascular Outcomes in Men with ED: Propensity-Weighted Hazard Ratios over 12 Months

Friday, May 15, 2026 3:30 PM to 5:30 PM · 1 hr. 59 min. (America/New_York)

146C

Abstract

Sessions

IP22: Sexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy I

Friday, May 15, 2026 3:30 PM to 5:30 PM

Log in

See all the content and easy-to-use features by logging in or registering!